PL2201376T3 - Nowy biomarker do monitorowania rozwoju chorób i do oceny skuteczności leczenia - Google Patents

Nowy biomarker do monitorowania rozwoju chorób i do oceny skuteczności leczenia

Info

Publication number
PL2201376T3
PL2201376T3 PL08842581T PL08842581T PL2201376T3 PL 2201376 T3 PL2201376 T3 PL 2201376T3 PL 08842581 T PL08842581 T PL 08842581T PL 08842581 T PL08842581 T PL 08842581T PL 2201376 T3 PL2201376 T3 PL 2201376T3
Authority
PL
Poland
Prior art keywords
therapies
assessing
efficacy
diseases
new biomarker
Prior art date
Application number
PL08842581T
Other languages
English (en)
Inventor
Sirpa Jalkanen
Marko Salmi
Markku Jalkanen
Original Assignee
Faron Pharmaceuticals Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faron Pharmaceuticals Oy filed Critical Faron Pharmaceuticals Oy
Publication of PL2201376T3 publication Critical patent/PL2201376T3/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
PL08842581T 2007-10-24 2008-10-15 Nowy biomarker do monitorowania rozwoju chorób i do oceny skuteczności leczenia PL2201376T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI20070795A FI20070795A0 (fi) 2007-10-24 2007-10-24 Uusi biomarkkeri sairauksien kehittämisen tarkkailuun ja terapioiden tehon arviointiin
EP08842581A EP2201376B1 (en) 2007-10-24 2008-10-15 A new biomarker for monitoring development of diseases and assessing the efficacy of therapies
PCT/FI2008/050576 WO2009053523A1 (en) 2007-10-24 2008-10-15 A new biomarker for monitoring development of diseases and assessing the efficacy of therapies

Publications (1)

Publication Number Publication Date
PL2201376T3 true PL2201376T3 (pl) 2013-01-31

Family

ID=38656804

Family Applications (2)

Application Number Title Priority Date Filing Date
PL08842581T PL2201376T3 (pl) 2007-10-24 2008-10-15 Nowy biomarker do monitorowania rozwoju chorób i do oceny skuteczności leczenia
PL12002502T PL2503338T3 (pl) 2007-10-24 2008-10-15 CD73 jako biomarker do monitorowania rozwoju choroby i oceny skuteczności terapii

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL12002502T PL2503338T3 (pl) 2007-10-24 2008-10-15 CD73 jako biomarker do monitorowania rozwoju choroby i oceny skuteczności terapii

Country Status (14)

Country Link
US (1) US20100209942A1 (pl)
EP (2) EP2201376B1 (pl)
JP (2) JP4982610B2 (pl)
KR (2) KR20160029869A (pl)
CA (1) CA2702635A1 (pl)
CY (2) CY1113403T1 (pl)
DK (2) DK2503338T3 (pl)
ES (2) ES2389751T3 (pl)
FI (1) FI20070795A0 (pl)
HR (2) HRP20120743T1 (pl)
PL (2) PL2201376T3 (pl)
PT (2) PT2201376E (pl)
SI (2) SI2201376T1 (pl)
WO (1) WO2009053523A1 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122018069446B8 (pt) 2008-01-18 2021-07-27 Harvard College método in vitro para detectar a presença de um célula de câncer em um indivíduo
EP2596349B1 (en) 2010-07-23 2017-12-13 President and Fellows of Harvard College Methods of detecting cardiovascular diseases or conditions
WO2012012717A1 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods of detecting prenatal or pregnancy-related diseases or conditions
AU2011280997A1 (en) 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting autoimmune or immune-related diseases or conditions
KR20130041961A (ko) 2010-07-23 2013-04-25 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 체액에서 질환 또는 상태의 특징을 검출하는 방법
KR20130041962A (ko) 2010-07-23 2013-04-25 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 식작용 세포를 사용하여 질환 또는 상태를 검출하는 방법
MX2014015425A (es) 2012-06-15 2015-07-14 Harry Stylli Metodos para detectar enfermedades o condiciones.
KR20150035818A (ko) 2012-06-15 2015-04-07 해리 스타일리 순환 병든 세포를 사용하여 질환 또는 병태를 검출하는 방법
LT2956772T (lt) 2013-02-14 2018-10-25 Faron Pharmaceuticals Oy Su ūminiu respiracinio distreso sindromu (ards) susijusių biologinių žymenų nustatymo būdas, ards raidos ir gydymo stebėsenos būdas pacientuose
EP2965086A4 (en) 2013-03-09 2017-02-08 Harry Stylli Methods of detecting prostate cancer
EP4202441A3 (en) 2013-03-09 2023-07-26 Immunis.AI, Inc. Gene expression profile in macrophages for the diagnosis of cancer
WO2016040843A1 (en) 2014-09-11 2016-03-17 Harry Stylli Methods of detecting prostate cancer
CN107250157B (zh) 2014-11-21 2021-06-29 百时美施贵宝公司 包含修饰的重链恒定区的抗体
ME03806B (me) 2014-11-21 2021-04-20 Bristol Myers Squibb Co Antitela protiv cd73 i njihova upotreba
GB201706747D0 (en) 2017-04-27 2017-06-14 Queen Mary Method and apparatus for determining the efficacy of statins for treating inflammatory diseases in idividual patients

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002515965A (ja) * 1995-08-18 2002-05-28 ダブリュー． ランドリ，ドナルド 抗体触媒反応の調節による有機化合物の検出
EP0862652A1 (en) 1995-10-13 1998-09-09 IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY & MEDICINE Methods for predicting the outcome of persistent hbv infection and the outcome of cytokine therapy
HUP0002003A3 (en) 2000-05-24 2003-01-28 Pronuk Biotechnologia Kft Process and reagent-kit for determining of 5'-nucleotidase activity
CA2439961A1 (en) * 2001-03-27 2002-10-03 Zymogenetics, Inc. Human cytokine receptor
WO2004079013A1 (en) * 2003-03-03 2004-09-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer
FI20030467A0 (fi) * 2003-03-28 2003-03-28 Sirpa Jalkanen Menetelmä tulehdustilojen hoitamiseen
PL1608400T3 (pl) * 2003-03-28 2010-11-30 Faron Pharmaceuticals Oy Podwyższanie poziomu adenozyny przez indukowaną przez cytokiny ekspresję CD73
WO2005000860A2 (en) * 2003-06-03 2005-01-06 The Regents Of The University Of California Compositions and methods for treatment of disease with acetylated disaccharides
US8129114B2 (en) * 2005-08-24 2012-03-06 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
FI20051003A0 (fi) 2005-10-07 2005-10-07 Faron Pharmaceuticals Oy Menetelmä iskemiareperfuusiovaurion tai monielinhäiriön hoitamiseksi tai estämiseksi
EP2021350B1 (en) * 2006-03-21 2016-12-21 Rheinische Friedrich-Wilhelms-Universität Bonn Phosphorylated a2a receptor agonists
WO2008008284A2 (en) * 2006-07-14 2008-01-17 The Regents Of The University Of California Cancer biomarkers and methods of use threof

Also Published As

Publication number Publication date
KR20160029869A (ko) 2016-03-15
FI20070795A0 (fi) 2007-10-24
EP2503338B1 (en) 2014-12-24
DK2503338T3 (en) 2015-03-09
EP2503338A3 (en) 2013-03-13
JP2011501176A (ja) 2011-01-06
PT2201376E (pt) 2012-08-20
KR20100059902A (ko) 2010-06-04
SI2503338T1 (sl) 2015-06-30
HRP20150181T1 (hr) 2015-06-19
JP4982610B2 (ja) 2012-07-25
DK2201376T3 (da) 2012-10-15
EP2503338A2 (en) 2012-09-26
EP2201376B1 (en) 2012-08-08
PT2503338E (pt) 2015-03-05
JP2012159514A (ja) 2012-08-23
JP5619810B2 (ja) 2014-11-05
CY1116089T1 (el) 2017-02-08
EP2201376A4 (en) 2011-03-23
WO2009053523A1 (en) 2009-04-30
CY1113403T1 (el) 2016-06-22
PL2503338T3 (pl) 2015-06-30
ES2389751T3 (es) 2012-10-31
HRP20120743T1 (hr) 2012-10-31
EP2201376A1 (en) 2010-06-30
SI2201376T1 (sl) 2012-09-28
CA2702635A1 (en) 2009-04-30
ES2532361T3 (es) 2015-03-26
US20100209942A1 (en) 2010-08-19

Similar Documents

Publication Publication Date Title
EP2201376A4 (en) NEW BIOMARKER FOR MONITORING THE DEVELOPMENT OF DISEASES AND TESTING THE EFFECTIVENESS OF THERAPIES
GB0724735D0 (en) Methods and biomarkers for diagnosing and monitoring psychotic disorders
GB0701626D0 (en) Methods and biomarkers for diagnosing and monitoring psychotic disorders
IL219210A0 (en) Biomarkers and methods for measuring and monitoring inflammatory disease activity
ZA201108907B (en) New biomarkers for assessing kidney diseases
EP2043617A4 (en) SYSTEM FOR MANAGING THERAPY AND MONITORING SUBSTANCE TO BE ANALYZED AND METHODS THEREFOR
EP2024745A4 (en) BIOLOGICAL ASSAYS FOR THE DIAGNOSIS AND EVALUATION OF FABRY DISEASE TREATMENT OPTIONS
IL179930A0 (en) Tvms - a total view monitoring system
EP2274699A4 (en) METHOD AND SYSTEMS FOR EVALUATING CLINICAL RESULTS
GB2450351B (en) Monitoring an Immunoassay
EP2079484A4 (en) MONITORING OF CANCER STEM CELLS
EP2486233A4 (en) Formation testing planning and monitoring
EP2393416A4 (en) METHOD AND DEVICE FOR THE QUANTITATIVE DETERMINATION OF THE PROBABILITY OF A DISEASE
GB0521098D0 (en) Methods for diagnosing and monitoring psychotic disorders
GB2444848B (en) Battery life monitor
GB0724200D0 (en) Battery life monitor
GB0720433D0 (en) Usage monitoring
EP2209565A4 (en) MONITORING INDEPENDENT VIBRATORS
EP2057570A4 (en) MONITORING CLINICAL DATA
GB0622351D0 (en) Non-invasive monitoring
EP2117544A4 (en) BIOMARKER FOR IDENTIFYING REACTIVATION OF STAT3 AFTER INHIBITION OF SRC
GB0822262D0 (en) Monitoring computer usage
GB0822087D0 (en) Monitoring computer usage
GB0603388D0 (en) Exhaler device for monitoring disease
AU2009902698A0 (en) Agents and methods for diagnosing a condition